Skip to contentN
NovoCure Ltd
N
NVCRNovoCure Ltd Q2 2024 · 10-Q
Revenue$150.36M$150.36M+19.3% vs Q2 2023 Net Income-$33.38M-$33.38MN/M vs Q2 2023 EPS Diluted-$0.31-$0.31N/M vs Q2 2023 Gross Profit$115,702,000+25.7% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
NovoCure Ltd · CIK 1645113 · Engraved from SEC EDGAR
Operating Cash Flow-$1,720,000N/M Free Cash Flowderived-$13,166,000N/M Margins · derivedGross margin77.0%+3.9 pt vs Q2 2023
Operating margin-22.3%+27.4 pt vs Q2 2023
Net margin-22.2%+23.4 pt vs Q2 2023
ended Jun 30, 2024 · filed Jul 25, 2024 · 25 d after period end